Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Viagenpumatucel-L - Heat Biologics

Drug Profile

Viagenpumatucel-L - Heat Biologics

Alternative Names: Ad100-gp96Ig-HLA A1; Gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line; gp96-Ig lung cancer vaccine - Heat Biologics/University of Miami; HS-110; HS-L1

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Miami
  • Developer Heat Biologics
  • Class Adjuvants; Cancer vaccines
  • Mechanism of Action Heat-shock protein stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 21 Nov 2019 Interim efficacy data from a phase II trial in Non-small cell lung cancer released by Heat Biologics
  • 12 Nov 2019 Interim efficacy and safety data from phase II trial in Non-small cell lung cancer released by Heat Biologics
  • 08 Oct 2019 Heat Biologics plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA in November 2019 (Intradermal) (NCT04116710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top